These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 10358402)

  • 1. [Treatment strategies in essential arterial hypertension].
    Waeber B
    Rev Prat; 1999 Mar; 49(5):520-5. PubMed ID: 10358402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ESH-ESC guidelines for the management of hypertension.
    Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B
    Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Managing hypertension in high-risk patients: lessons and promises from the STRATHE and ADVANCE trials.
    Waeber B
    J Hypertens Suppl; 2006 May; 24(3):S19-27. PubMed ID: 16723862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose combinations versus monotherapies in the treatment of hypertension.
    Waeber B; Brunner HR
    J Hypertens Suppl; 1997 Mar; 15(2):S17-20. PubMed ID: 9218193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
    Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA
    J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined therapy in the treatment of hypertension.
    Escobar C; Barrios V
    Fundam Clin Pharmacol; 2010 Feb; 24(1):3-8. PubMed ID: 19682088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple drug therapy in the treatment of essential hypertension.
    Hockenberry B
    Nurs Clin North Am; 1991 Jun; 26(2):417-36. PubMed ID: 2047290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The future of antihypertensive treatment.
    Israili ZH; Hernández-Hernández R; Valasco M
    Am J Ther; 2007; 14(2):121-34. PubMed ID: 17414579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcium channel blockers in hypertension. Is there still a controversy?
    Izzo JL
    Aging Clin Exp Res; 2005 Aug; 17(4 Suppl):1-5. PubMed ID: 16640168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ambulatory blood pressure monitoring in the prediction of cardiovascular events and effects of chronotherapy: rationale and design of the MAPEC study.
    Hermida RC
    Chronobiol Int; 2007; 24(4):749-75. PubMed ID: 17701685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal.
    Zanchetti A; Grassi G; Mancia G
    J Hypertens; 2009 May; 27(5):923-34. PubMed ID: 19381107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose fixed combination of bisoprolol/hydrochlorothiazide as first line for hypertension: a review of the rationale and clinical evidence.
    Papadopoulos DP; Papademetriou V
    Angiology; 2009; 60(5):601-7. PubMed ID: 19028769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk stratification for the prevention of cardiovascular complications of hypertension.
    Girerd X; Giral P
    Curr Med Res Opin; 2004 Jul; 20(7):1137-42. PubMed ID: 15265258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 'Beyond blood pressure' means multiple risk factor intervention, not pleiotropic antihypertensive drugs.
    Staessen JA; Thijs L; Li Y; Kuznetsova T; Richart T; Wang J; Birkenhäger WH
    Curr Opin Cardiol; 2007 Jul; 22(4):335-43. PubMed ID: 17556887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacology of antihypertensive therapy.
    Taylor AA; Pool JL
    Semin Nephrol; 2005 Jul; 25(4):215-26. PubMed ID: 16202694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination versus Monotherapy as Initial Treatment in Hypertension.
    Holzgreve H
    Herz; 2003 Dec; 28(8):725-32. PubMed ID: 14689107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The multifactorial nature of hypertension: the greatest challenge for its treatment?
    Waeber B; Brunner HR; ;
    J Hypertens Suppl; 2001 Sep; 19(3):S9-16. PubMed ID: 11713851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood pressure lowering, not vascular mechanism of action, is the primary determinant of clinical outcome.
    Leenen FH
    Can J Cardiol; 2004 Aug; 20 Suppl B():77B-82B. PubMed ID: 15309209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.